Trial Profile
A Randomized, Double-Blind, Active-Controlled Study of Patients With Cardiovascular Disease and Diabetes Mellitus Not Adequately Controlled With Simvastatin or Atorvastatin: Comparison of Switching to Combination Tablet Ezetimibe/Simvastatin vs Switching to Rosuvastatin or Doubling the Statin Dose
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 05 May 2022
Price :
$35
*
At a glance
- Drugs Ezetimibe/simvastatin (Primary) ; Atorvastatin; Rosuvastatin; Simvastatin
- Indications Cardiovascular disorders; Hyperlipidaemia
- Focus Therapeutic Use
- Acronyms COMPLETED
- Sponsors Merck Sharp & Dohme; Organon
- 16 Nov 2011 Results presented at the 84th Annual Scientific Sessions of the American Heart Association.
- 25 Mar 2011 Actual end date (Mar 2011) added as reported by ClinicalTrials.gov.
- 25 Mar 2011 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.